Zoetis — Dormosedan® Gel 3 ml Syringe (Rx)
$29.97
Please note that this item requires a veterinarian's prescription.
Convenient ways to do that are:
Convenient ways to do that are:
- Your veterinarian can contact us by fax/phone.
- Create an account or simply sign in if you have a prescription already on file.
Vaccine and Rx items are not returnable.
About This Product
SKU6432100015594
BrandZoetis
Dormosedan® gel Is a Synthetic Alpha2-adrenoreceptor Agonist with Sedative Properties with Detomidine Hydrochloride as Medicinal Ingredient.
Dormosedan Gel produces sedation when administered sublingually at 0.040 mg/kg body weight (0.018 mg/lb body weight). Dormosedan Gel must be placed beneath the tongue of the horse and is not meant to be swallowed. The dosing syringe delivers the product in 0.25 mL increments.
Contraindications & Warnings
Cautions:
Dormosedan Gel must be placed beneath the tongue of the horse. Unlike most oral veterinary products, this product is not meant to be swallowed. Swallowing could result in ineffectiveness. DormosedanGel does not provide analgesia. Do not use for painful procedures. Do not use with other sedative drugs because the effects may be additive. Repeat dosing has not been evaluated.
Dormosedan Gel must be placed beneath the tongue of the horse. Unlike most oral veterinary products, this product is not meant to be swallowed. Swallowing could result in ineffectiveness. DormosedanGel does not provide analgesia. Do not use for painful procedures. Do not use with other sedative drugs because the effects may be additive. Repeat dosing has not been evaluated.
The use of an alpha2-agonist reversal agent with Dormosedan Gel has not been evaluated. Before initiating any procedure, allow sedation to fully develop. Nervous or excited horses with high levels of endogenous catecholamines may exhibit a reduced pharmacological response to alpha2-adrenoceptor agonists like detomidine. In agitated horses, the onset of sedative effects could be slowed, or the depth and duration of effects could be diminished or nonexistent. When the product is administered, the animal should be allowed to rest in a quiet place for a minimum of 40 minutes.
Do not use Dormosedan Gel in horses with cardiovascular disease, respiratory disorders, liver or kidney diseases, or in conditions of shock, severe debilitation, or stress due to extreme heat, cold, fatigue, or high altitude. Protect treated horses from temperature extremes. As with all alpha2-adrenoceptor agonists, the potential for isolated cases of hypersensitivity exists, including paradoxical response (excitation). DormosedanGel has not been evaluated in ponies, miniature horses, or horses younger than one year of age.
Dormosedan Gel has not been evaluated for use in breeding horses, and pregnant or lactating mares.
Warnings:
Do not use in horses intended for food. Keep out of reach of children. Use impermeable gloves during drug administration and during procedures that require contact with the horse’s mouth. Following sublingual administration of detomidine hydrochloride oromucosal gel, drug concentrations up to 0.072 mg/mL were measured at 30 minutes post-treatment in equine saliva, equivalent to less than one percent of the original detomidine concentration in the gel. Mean drug concentrations fall to less than 0.010 mg/mL by 2 hours after drug administration, after which a slow decline occurs for several additional hours.
Do not use in horses intended for food. Keep out of reach of children. Use impermeable gloves during drug administration and during procedures that require contact with the horse’s mouth. Following sublingual administration of detomidine hydrochloride oromucosal gel, drug concentrations up to 0.072 mg/mL were measured at 30 minutes post-treatment in equine saliva, equivalent to less than one percent of the original detomidine concentration in the gel. Mean drug concentrations fall to less than 0.010 mg/mL by 2 hours after drug administration, after which a slow decline occurs for several additional hours.
Dormosedan Gel can be absorbed following direct exposure to skin, eyes, or mouth, and may cause irritation. Skin and mucosal contact with the product should be avoided. In case of accidental eye exposure, rinse abundantly with fresh water. In case of accidental skin exposure, wash with soap and water. Remove contaminated clothing.
Appropriate precautions should be taken while handling and using gel syringes. Accidental exposure could cause adverse reactions, including sedation, hypotension, and bradycardia. Seek medical attention immediately but do not drive because sedation or changes in blood pressure may occur. Individuals with cardiovascular disease (for example, hypertension or ischemic heart disease) should take special precautions to avoid exposure to this product.
Caution should be exercised when handling sedated animals. Handling or any other sudden stimuli, including noise, may cause a defense reaction in an animal that appears to be heavily sedated. Rare cases of human abuse of detomidine products have been reported.
Dormosedan Gel should be managed to prevent the risk of diversion, through such measures as restriction of access and the use of drug accountability procedures appropriate to the clinical setting.
Pharmaceutical Precautions
Store between 15 and 30°C. Protect from light.